PCRX News and Press, Pacira BioSciences Inc. From 01/21/24

2024-01-21 06:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-10 14:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-05 04:17:23 ET More on Pacira BioSciences Pacira BioSciences: Preparing For A Pivotal Q3 Earnings Pacira appoints Frank Lee as chief executive officer Pacira wins FDA approval for two new indications of Exparel For further details see: Pacira BioS...

TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited total revenue of $675.0 million for the year ended December 31, 2023,...

2024-01-03 16:34:46 ET Gainers: iHeartMedia ( IHRT ) +10% . Arcutis Biotherapeutics ( ARQT ) +8% . Cipher Mining  ( CIFR ) +7% . Pacira BioSciences ( PCRX ) +6% . Argo Blockchain  ( ARBK ) +6% . Losers: Cal-Main...

TAMPA, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 42 nd Annual J.P. Morgan Healthcare Conference at 8:15 AM PT (11:15 AM EST) on Wednesday, January 10, 2024. Live audio of the event can be accessed by visitin...

2023-12-21 20:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-21 07:55:30 ET More on Pacira BioSciences Pacira BioSciences: Preparing For A Pivotal Q3 Earnings Pacira wins FDA approval for two new indications of Exparel Pacira BioSciences Non-GAAP EPS of $0.72 misses by $0.06, revenue of $163.93M misses by $9M F...

-- Transformational Leader Brings Three Decades of Global Experience in Pharmaceutical and Biotechnology Product Development and Commercialization -- -- Paul J. Hastings Named Chair of the Board -- -- Dave Stack to Remain in Advisory Role through August 2025 -- TAMPA,...

2023-11-10 09:06:08 ET More on Pacira BioSciences Pacira BioSciences, Inc. 2023 Q3 - Results - Earnings Call Presentation Pacira BioSciences, Inc. (PCRX) Q3 2023 Earnings Call Transcript Pacira BioSciences: Preparing For A Pivotal Q3 Earnings Pacira BioScienc...